CLINICAL NEWS
ously treated patients, the question of how to optimally sequence therapy
for people with MCL remains. “It could be argued that it is reasonable to
‘save’ ibrutinib for use in patients who are refractory to other standard
therapies,” Dr. Martin and colleagues wrote. “Of note, the median OS
from diagnosis of the entire cohort was only 54 months, suggesting that
even in the ibrutinib and lenalidomide era, there remains considerable
room for improvement.”
“Clinicians should be prepared for the eventual, inevitable relapse
that happens when a person with MCL is treated with ibrutinib,” Dr.
Martin told ASH Clinical News. “Clinicians, scientists, and pharmaceutical compa